Assessment of suicidal behavior and risk remains a source of apprehension for clinicians, clinical researchers, and the pharmaceutical industry. This apprehension has been exacerbated by U.S. Food and Drug Administration (FDA) “black box” warnings for antidepressants used with children and adolescents and by an increasingly litigious society. Much has been learned about risk factors and predicting suicide in the past decade, as succinctly summarized in a recent commentary by Brent (1), who suggested that the field should be moving on to researching prevention, concomitant health risks such as substance abuse, and causal mechanisms. Even with this progress, however, dissemination of new precision measurements and training to improve suicide assessment lags behind (2). Well-designed, precisely defined instruments for suicide assessment lessen apprehension about identifying potential suicidal behavior and increase precision in diagnosis as well as in treatment, prediction of risk, and monitoring of suicidal behavior, for clinicians, researchers, and the pharmaceutical industry (3). In this issue, Posner et al. (4) describe the psychometric properties of a new instrument, the Columbia–Suicide Severity Rating Scale (C-SSRS).